Bayer Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Bayer Intellectual Property Gmbh

Miles Inc.

Bayer Schering Pharma Ag

Bayer Animal Health Gmbh

Bayeraktiengesellschaft

Xention Limited

Heinrich Meier

Rudolf Schohe-Loop

Bodo Junge

Zhan Gao

Wolfgang Hartwig

Teunis Schuurman

Bernard Schmidt

Maarten De Jonge

Klemens Lustig

Chantal Fürstner

Dmitry Zubov

Jens Schamberger

Alexander Straub

Katja Zimmermann

Hanna Tinel

Martina Schäfer

Jens Ackerstaff

Adrian Tersteegen

Raimund Kast

Kirsten Börngen

Peter Fey

Joachim Mittendorf

Martina Delbeck

Johannes Kaulen

Kai Van Laak

Arnd Voerste

Udo Albus

Peter Kolkhof

Carsten Schmeck

Thomas Ernst Müller

Markus Heil

Michael Hahn

Josef Pernerstorfer

Dirk Denzer

Muneto Mogi

Jean-Marie-Viktor De Vry

Paul Naab

Nicole Diedrichs

Trevor S Abram

Frank Mauler

Peter Norman

Masaomi Tajimi

Noriyuki Yamamoto

Hiroshi Fujishima

Doris Gehring

Luisella Toschi

Björn Rosenstein

Axel Bouchon

Johanna Mosig

Achim Hermann

Dieter Lang

Ulrich Rosentreter

Jörg Keldenich

Harold C Kluender

Lars Bärfacker

Niels Lindner

Ulrich Niewohner

Daniel Meibom

Yolanda Cancho Grande

Klaus Urbahns

Ingo Flamme

Elisabeth Pook

Barbara Albrecht-Küpper

Dagmar Karthaus

Stefan Golz

Jean De Vry

Thomas Neubauer

Ulf Brüggemeier

Dirk Schneider

Carsten Terjung

Nigel J Cuthbert

Kersten Matthias Gericke

Damian Brockschnieder

Takeshi Yura

Dieter Moosmayer

Eckhard Bender

Hilary P Francis

Hubert Trübel

Yasuhiro Tsukimi

Andreas Geerts

Jan-Bernd Lenfers

Adam Nitsche

Phillip J Gardiner

Florian Kölling

Volker Hinz

Nicole Biber

Volker Badock

Jörg Meding

Thomas Müller

Hideki Miyatake Ondozabal

Verena Voehringer

Elke Reiβmüller

Elke Reissmuller

Andreas Timmermann

Hiroaki Yuasa

Jang Gupta

Fumihiko Hayashi

Stephen Moore

Alexander Schulz

Swen Allerheiligen

The present application relates to novel 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring.

2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders

The present application relates to novel substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones of formula (I), to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of lung inflammation disorders. 

Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereof

The present application relates to novel (2-phenylimidazo[1,2-a]pyridin-3-yl)methyl-substituted perhydropyrrolo[3,4-c]pyrrole derivatives, to methods for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apneas and central sleep apneas and snoring.

Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same

The present application relates to novel bicyclically substituted uracil derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases.

Bicyclically substituted uracils and the use thereof

The present invention relates to the use of cathepsin K and/or cathepsin S inhibitors in a method for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure.

Use of cathepsin K inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure

Substituted uracil derivatives of the compound of Formula (I), processes for their preparation, their use alone or in combinations for treatment and/or prophylaxis of diseases, and their use for preparing medicaments for treatment and/or prophylaxis of diseases. 

Substituted uracils and use thereof

Substituted uracil derivatives of formula (I), processes for their preparation, their use alone or in combinations for the treatment and/or prophylaxis of diseases, and their use for preparing medicaments for the treatment and/or prophylaxis of diseases.

Substituted uracils as chymase inhibitors

The present application relates to novel substituted 6-phenylnicotinic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prophylaxis of cardiovascular disorders, in particular dyslipidaemias, arteriosclerosis and heart failure.

Substituted 6-phenylnicotinic acids and their use

The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.

Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors

This invention relates to tetrahydro-quinolinylurea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-quinolinylurea derivative of the present invention has vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).

Tetrahydro-quinolinylurea derivatives

This invention relates to a hydroxy-tetrahydro-naphthalene or an urea derivative formula (I) and salts thereof which are useful as active ingredients of pharmaceutical preparations, wherein A represents formula (II) or (III) wherein # represents the connection position to the molecule and Q, Q, Qand Qare defined, and E represents formula (IV) or (V) wherein # represents the connection position to the molecule and Q, Q, Q, Q, Q, R, na, ma, Xand Rare defined.

Tetrahydro-naphthalene and urea derivatives

The invention relates to novel aryl and heteroaryl sulfonates of formula (Ia) and to methods for producing them and to novel aryl and heteroaryl sulfonates of formula (I) for treating and/or preventing diseases, especially for treating pain and neurodegenerative diseases, A representing (C-C)-aryl or 5-10-membered heteroaryl, D representing (C-C)-arylene or 5-10-membered heteroarylene, Rrepresenting (C-C)-alkyl, (C-C)-alkyl, the carbon chain being interrupted by one or two heteroatoms or groups chosen from the following group: &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;SO&#x2014; and &#x2014;SO&#x2014;, (C-C)-alkenyl or (C-C)-alkinyl, in formula (Ia); and Rrepresenting (C-C)-alkyl, (C-C)-alkyl, the carbon chain being interrupted by one or two heteroatoms or groups chosen from the following group: &#x2014;O&#x2014;, &#x2014;S&#x2014;,&#x2014;SO&#x2014; and &#x2014;SO&#x2014;, (C-C)-alkenyl or (C-C)-alkinyl.

Aryl and heteroaryl sulfonates

Growing community of inventors

Wuppertal, Germany

Heinrich Meier